ISHITA DRUGS & INDUSTRIES LTD.
Latest filings
Next results: Tue, 3 Nov · Financial Results- Board to approve September 2026 quarterly results · Results
- Routine SEBI compliance certificate filed for Q2 FY26 · Compliance
- Re-appointment of Director and Statutory Auditor approved at AGM · Management Changes
Snapshot
What the business is, and whether it's a good one at a fair price.
Manufactures pharmaceutical products at an Indian facility, generating Rs 14.66 crore of revenue in FY26. Raw materials make up 69.2% of revenue — the dominant cost — followed by employee costs at 9.4% and other operating expenses at 15.0%. The company is upgrading its manufacturing facility to comply with India's Revised Schedule M norms; as of December 2025, the new warehouse block was nearly complete and Rs 1.75 crore of capital work-in-progress sat on the balance sheet at year-end. It held Rs 12.60 crore of total assets, earned Rs 0.78 crore of net profit, and ran an 8.45% EBITDA margin in FY26. The filings do not break out revenue by product category or therapeutic segment, and the customer mix is not disclosed.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Concerns
Charts
How has the market priced it — with filings on the timeline?
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from ISHITA DRUGS & INDUSTRIES LTD.'s filed financials and exchange disclosures
What does ISHITA DRUGS & INDUSTRIES LTD. do?
ISHITA DRUGS & INDUSTRIES LTD. is a Pharmaceuticals & Biotechnology company listed on BSE.
Is ISHITA DRUGS & INDUSTRIES LTD. profitable?
Yes. Over the trailing twelve months ISHITA DRUGS & INDUSTRIES LTD. reported a net profit of ₹0.78 Cr on revenue of ₹15 Cr.
Does ISHITA DRUGS & INDUSTRIES LTD. pay a dividend?
Not in the latest reported year — ISHITA DRUGS & INDUSTRIES LTD.'s dividend payout for FY26 was nil.
Is ISHITA DRUGS & INDUSTRIES LTD. debt-free?
On a net basis, yes. It reported borrowings of ₹0.08 Cr on its 31 Mar 2026 balance sheet, but holds ₹0.06 Cr more cash than debt.
Is ISHITA DRUGS & INDUSTRIES LTD. expensive compared with its peers?
On trailing P/E, ISHITA DRUGS & INDUSTRIES LTD. ranks 77 of 158 in Pharmaceuticals — cheaper than 52% of them, against an industry median of 30.8×. This is a position, not a valuation judgement.
How much does the ISHITA DRUGS & INDUSTRIES LTD. share price move in a day?
On a typical session ISHITA DRUGS & INDUSTRIES LTD. moves 1.87% — that is the median absolute close-to-close move across its last 247 trading days. MarketPing measures each filing's price reaction against it.
When are ISHITA DRUGS & INDUSTRIES LTD.'s next results?
Financial Results on Tue, 3 Nov. MarketPing alerts you on WhatsApp the moment the filing lands.
Where can I track ISHITA DRUGS & INDUSTRIES LTD.'s announcements?
Every NSE and BSE filing by ISHITA DRUGS & INDUSTRIES LTD. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.